Nanobiose offers the unique expertise of its seasoned team of experts in immunotoxicology and immunological assessment to propose a comprehensive support to:
Because innovative healthcare products are developing fast to cover unmet needs.
As a consequence, there is an increasing need for a better characterization of their impact on human health, in particular their immunological safety.
In this context, Nanobiose founders realised the need to develop more predictive tools for a better in vitro assessment of the immunological safety of such products.
Nanobiose is a specialized company founded in july 2016 in Le Bourget du Lac (France), at the alpine crossroads of Europe. Nanobiose is dedicated to the immunological assessment of innovative products developed in the health sector ranging from:
Immunological safety is a field which is growing along with the progresses of innovative healthcare products, whether they are nanodrugs, nanoformulations, constrat agents for imaging, biopharmaceuticals, or dermocosmetics. This is a key component of the general safety profile of such compounds. For example, nanodrugs are subject to the same regulations than classical medecines. Those regulations are described in guidelines edited by the international regulatory authorities like the US Food and Drugs Administration or the European Medicines Agency. In the last years, those agencies regularly increased their requests for experimental assessments concerning the potential side effects of nanodrugs on the immune system, at both the short and the long term.